Skip to main content
. 2018 Nov 25;94(3):346–357. doi: 10.1002/ajh.25342

Figure 1.

Figure 1

Possible criteria for selection of TFR as a treatment option. All criteria green indicates strongly recommended. Any yellow criteria indicates only consider TFR in high‐priority circumstances (e.g. significant toxicity or planned pregnancy). Any red criteria indicates TFR not recommended except in a clinical trial. AP, advanced phase; BP, blast crisis; CML, chronic myeloid leukemia; CP, chronic phase; KD, kinase domain; MR, molecular response; TFR, treatment‐free remission; TKI, tyrosine kinase inhibitor. (Republished with permission of the American Society of Hematology, from Hughes TP, Ross DM. Moving treatment‐free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17‐23. © 2016 by The American Society of Hematology. Permission conveyed through Copyright Clearance Center, Inc.)